The first patient received their first dose on July 29, 2022. Food and Drug Administration (FDA) for the treatment of certain patients with advanced epithelioid sarcoma (ES) and ce. The primary objective is to evaluate the efficacy of tazemetostat for treatment of patients with RR FL who have mutations in EZH21 (Cohort 1).
🌍 HUTCHMED DRC (HCM) - Form 6-K Filing
Filing Date: 2022-08-01
Accepted: 2022-08-01 06:53:20
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: